Star Combo Pharma Valuation
Is S66 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of S66 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate S66's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate S66's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for S66?
Other financial metrics that can be useful for relative valuation.
What is S66's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | AU$16.21m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.4x |
Enterprise Value/EBITDA | 6.3x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does S66's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 30.8x | ||
MRAT Mustika Ratu | 1.9x | n/a | Rp163.5b |
8436 Takbo Group Holdings | 5.4x | n/a | HK$79.2m |
HRP Harper Hygienics | 101.1x | n/a | zł44.2m |
ERFO Laboratorio Farmaceutico Erfo | 14.8x | 25.3% | €10.5m |
S66 Star Combo Pharma | 33.4x | n/a | AU$16.2m |
Price-To-Earnings vs Peers: S66 is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the peer average (30.4x).
Price to Earnings Ratio vs Industry
How does S66's PE Ratio compare vs other companies in the Global Personal Products Industry?
Price-To-Earnings vs Industry: S66 is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the Global Personal Products industry average (24.6x).
Price to Earnings Ratio vs Fair Ratio
What is S66's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 33.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate S66's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.